Retatrutide, also known as LY3437943, is a peptide that activates three metabolic hormone receptors: GIP, GLP-1 and glucagon. It is being studied for its effects on body-weight regulation, glucose control and broader metabolic function.
Studied Uses
Retatrutide has been investigated in clinical research involving:
- Obesity and overweight
- Body-weight and body-composition changes
- Type 2 diabetes and glycaemic control
- Appetite and energy-balance regulation
- Metabolic dysfunction-associated liver fat
- Obesity-related complications, including knee osteoarthritis
- Cardiovascular and kidney outcomes in higher-risk populations
Phase 2 studies reported reductions in body weight and improvements in glycaemic control. In 2026, Lilly also announced positive results from several Phase 3 obesity and type 2 diabetes trials.
How It Works
Retatrutide acts as a single-molecule agonist at the GIP, GLP-1 and glucagon receptors.
GIP and GLP-1 receptor activation influences glucose-dependent insulin secretion, appetite signalling and food intake. Glucagon-receptor activation affects liver metabolism and energy expenditure. Researchers are studying whether combining all three receptor pathways can produce complementary effects on glucose regulation, appetite, energy balance and body weight.
Product Details
Product: Retatrutide
Strength: 60 mg
Form: Lyophilized powder
Presentation: Single vial
Reviews
There are no reviews yet.